Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion

Asian Pacific Journal of Tropical Medicine

Volumn 5, Issue 3, 2012, Pages 239-242

  Zhang, Yu ^a   Yu, Li Ke ^a   Xia, Ning ^a  

^a NANJING CHEST HOSPITAL   (China)

Author keywords

Endostatin; Lung cancer; Pleural effusion; Serum; Vascular endothelial growth factor

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; ENDOSTATIN; TUMOR MARKER; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EMPYEMA; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; PLEURA FLUID; PNEUMONIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TISSUE LEVEL; TUBERCULOUS PLEURISY;

ADULT; AGED; CARCINOEMBRYONIC ANTIGEN; EARLY DETECTION OF CANCER; ENDOSTATINS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURA; PLEURAL EFFUSION; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863020803     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1995-7645(12)60032-7     Document Type: Article

References (20)

1. Sahn SA Pleural diseases related to metastatic malignancies. Eur Respir J 1997, 10(8):1907-1913.
2. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88(2):277-285.
3. Rosca EV, Koskimaki JE, Rivera CG, Pandey NB, Tamiz AP, Popel AS Anti-angiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol 2011, 12(8):1101-1116.
4. Koniari I, Koletti B, Apostolakis E Vascular endothelial growth factor with tumour growth factor-beta, endostatin, proteinases or cytokines might be useful for differential diagnosis of pleural effusions. Interact Cardiovasc Thorac Surg 2011, 12(3):424-425.
5. Fiorelli A, Vicidomini G, Di Domenico M, Napolitano F, Messina G, Morgillo F, et al. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. Interact Cardiovasc Thorac Surg 2011, 12(3):420-424.
6. Chen ML, Liu F, Li XQ The research for serum endostatin level in early diagnosis of lung cancer. Int J Lab Med 2009, 30(1):39-40.
7. Maskell NA, Butland RJ BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003, 58(Suppl 2):ii8-i17. PMID: 12728146.
8. Light RW Pleural effusion. N Engl J Med 2002, 346(25):1971-1977.
9. Loddenkemper R Medical thoracoscopy. Textbook of pleural diseases 2003, 498-512. Arnold, London. R.W. Light, Y.C. Gary Lee (Eds.).
10. Skovseth DK, Veuger MJT, Sorensen DR, De Angelis PM, Haraldsen G Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis and perivascular cell recruitment in vivo. Blood 2005, 105(3):1044-1051.
11. Suzuki M, Iizasa T, Ko E, Baba M, Saitoh Y, Shibuya K, et al. Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002, 35(1):29-34.
12. Zheng MJ Endostatin derivative angiogenesis inhibitors. Chin Med J 2009, 122(16):1947-1951.
13. Karamouzis MV, Moschos SJ The use of endostatin in the treatment of solid tumors. Expert Opin Biol Ther 2009, 9(5):641-648.
14. Dvorak HF, Weaver VM, Tlsty TD, Bergers G Tumor microenvironment and progression. J Surg Oncol 2011, 103(6):468-474.
15. Chouaib S, Kieda C, Benlalam H, Noman MZ, Mami-Chouaib F, Rüegg C Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol 2010, 30(6):529-545.
16. Grove CS, Lee YC Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002, 8:294-301.
17. Hiratsuka S Vasculogenensis, angiogenesis and special features of tumor blood vessels. Front Biosci 2011, 16:1413-1427.
18. Bremnes RM, Camps C, Sirera R Angiogenesis in non-small cell lung cancer:the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006, 51:143-158.
19. Subramanian J, Morgensztern D, Govindan R Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Lung Cancer 2010, 11(5):311-319.
20. Shi HZ, Liang QL, Jiang J, Qin XJ, Yang HB Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: A meta-analysis. Respirology 2008, 13(4):518-527.